Abstract：
The future development of personalized nuclear medicine relies on the availability of novel medical radionuclides. In particular, radiometals are attracting considerable interest since they can be used to label both proteins and peptides. Among them, the β+-emitter 68Ga is widely used in nuclear medicine for positron emission tomography (PET). It is used in theranostics as the diagnostic partner of the therapeutic β--emitters 177Lu and 90Y for the treatment of a wide range of diseases, including prostate cancer. Currently, 68Ga is usually obtained via 68Ge/68Ga generators. However, their availability, high price and limited produced radioactivity per elution are a major barrier for a wider use of the 68Ga-based diagnostic radiotracers. A promising solution is the production of 68Ga by means of proton irradiation of enriched 68Zn liquid or solid targets. Along this line, a research program is ongoing at the Bern medical cyclotron, equipped with a solid target station. In this paper, we report on the measurements of 68Ga, 67Ga and 66Ga production cross-sections using natural Zn and enriched 68Zn material, which served as the basis to perform optimized 68Ga production tests with enriched 68Zn solid targets.
摘要：
个性化核医学的未来发展依赖于新型医用放射性核素的可用性。特别是,放射性金属吸引了相当大的兴趣，因为它们可用于标记蛋白质和肽。其中,β+-发射极68Ga在核医学中广泛用于正电子发射断层扫描（PET）。它在治疗中用作治疗β-发射器177Lu和90Y的诊断伙伴，用于治疗多种疾病，包括前列腺癌.目前,68Ga通常通过68Ge/68Ga发生器获得。然而,其可用性,高价格和每次洗脱产生的有限放射性是更广泛使用68Ga基诊断放射性示踪剂的主要障碍。一个有希望的解决方案是通过富集的68Zn液体或固体靶的质子辐照来生产68Ga。沿着这条线,伯尔尼医疗回旋加速器正在进行一项研究计划，配备了一个坚实的目标站。在本文中,我们报告了68Ga的测量结果，使用天然Zn和富集68Zn材料的67Ga和66Ga生产横截面，作为使用富集的68Zn固体靶进行优化的68Ga生产测试的基础。
